Sunday, August 1, 2021

Chasing Allergan, Eyenovia hits endpoint in vision phase 3

A phase 3 clinical trial of Eyenovia’s MicroLine in patients with age-related long-sightedness has hit its primary endpoint. The formulation has the same active ingredient, pilocarpine, as a near-approval Allergan drug but is administered via a dispenser designed to improve on conventional eyedroppers. 

Pilocarpine is a muscarinic cholinergic agonist that is already used to reduce pressure inside the eye. In recent years, Allergan, Eyenovia and a clutch of other companies have worked to show pilocarpine and other miotic agents can counter the long-sightedness that develops in people after the age of 40. The condition, known as presbyopia, is typically corrected using reading glasses.

New York-based Eyenovia took a step toward establishing MicroLine as an alternative treatment this week when it reported top-line results from its VISION-1 study. The phase 3 clinical trial randomized 84 patients to receive one of two doses of pilocarpine or placebo.

Eyenovia linked MicroLine to a statistically significant improvement over placebo in the proportion of patients who experienced a three-line or greater improvement on a vision test in low light conditions two hours after treatment. The company is yet to share further efficacy information. On the safety front, Eyenovia said MicroLine was very well tolerated, causing only mild adverse events.

Buoyed by the findings, Eyenovia outlined plans to run a second phase 3 registration study. The plan is to use data from the two clinical trials to support an application for approval to the FDA.

Eyenovia is likely to face competition for the market. AbbVie’s Allergan filed for FDA approval of its pilocarpine ophthalmic solution in presbyopia in February on the strength of a phase 3 program that enrolled 750 patients. The two Allergan trials assessed the change in vision after 30 days of daily dosing with its pilocarpine eye drops.

Allergan looks set to get to market before Eyenovia and is a bigger organization. Eyenovia is looking to its Optejet dispenser as a source of differentiation, pointing to evidence that it delivers more consistent doses than typical eyedroppers.

Source link

Stay Connected


Latest Articles

Need to create vigilance and awareness on zoonotic diseases: India’s Health Minister

The COVID-19 pandemic has highlighted the need of creating vigilance and awareness on zoonotic diseases, informed Union Health Minister Mansukh Mandaviya while virtually inaugurating...

Covid’s second wave proves lethal for pregnant women

At SVP Hospital in Ahmedabad – one of the major Covid-19 hospitals of the city – 148 pregnant women with Covid-19 infection were admitted...

7 Tips to Keep Your Gut Healthy

This is common to say health (and illness) starts in your gut. If you have poor gut health, you’ll experience anything from wrinkled skin, to...

SII making first batch of Covovax: Poonawalla

The first batch of Covovax, a Covid-19 vaccine developed by Novavax Inc, is being manufactured at the Serum Institute of India's Pune facility, SII...

Sputnik V is safest among all Covid-19 vaccines, no deaths recorded: Buenos Aires study

A study by the Buenos Aires Ministry of Health to monitor the safety of the Sputnik V vaccine against Covid-19 confirmed on Thursday that...